Table 5 Prescription of the combined treatment
2020 | ||||
De novo HF without previous heart disease | De novo with previous heart disease | Non-de novo | ||
Admission | 4(3.0) | 0 | 0 | 4(4.4) |
Discharge | 10(7.4) | 1 (4.0) | 1(5.0) | 8(8.9) |
P | 0.070 | - | - | 0.219 |
Difference % (CI95%) | 4.4(-0.3/5.9) | 4.0(0.1/20.4) | 5.0(0.1/24.9) | 4.5(-1.9/6.6) |
2021 | ||||
Global | De novo HF without previous heart disease | De novo with previous heart disease | Non-de novo | |
Admission | 21(8.0) | 0 | 0 | 21(12.4) |
Discharge | 55(21.1) | 10(22.2) | 6(13.0) | 39(22.9) |
P | < 0.001 | - | - | 0.001 |
Difference % (CI95%) | 13.1(8.2/17.9) | 22.2(9.0/35.5) | 13.0(2.2/23.9) | 10.5(4.5/16.5) |
2022 | ||||
Global | De novo HF without previous heart disease | De novo with previous heart disease | Non-de novo | |
Admission | 19(9.2) | 0 | 1(2.4) | 18(14.2) |
Discharge | 67(32.5) | 14(36.8) | 18(43.9) | 35(27.6) |
p | < 0.001 | - | < 0.001 | 0.001 |
Difference % (CI95%) | 23.3(17.1/29.5) | 36.8(20.2/53.5) | 41.5(21.9/46.4) | 13.4(6.4/20.4) |
2020–2022 | ||||
Global | De novo HF without previous heart disease | De novo with previous heart disease | Non-de novo | |
Admission | 44(7.3) | 0 | 1(0.9) | 43(11.1) |
Discharge | 132(21.9) | 25(23.1) | 25(23.4) | 82(21.1) |
p | < 0.001 | - | < 0.001 | < 0.001 |
Difference % (CI95%) | 14.6(11.4/17.8) | 23.1(14.1/31.6) | 22.5(13.2/29.4) | 10(6.3/13.8) |